anti-CD274 [B7-H1/PD-L1] (human), mAb (ANC6H1) (FITC)
|Synonyms||B7-H1; Programmed Cell Death 1 Ligand 1; PD-L1; PDCD1 Ligand 1|
|Product Type||Monoclonal Antibody|
|Immunogen/Antigen||Recombinant human CD274(B7-H1).|
|Formulation||50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 5% Glycerol, 0.2% BSA, 0.04% NaN3 (as a preservative).|
|Isotype Negative Control|
|Other Product Data||
Click here for Original Manufacturer Product Datasheet
|Declaration||Manufactured by Ancell Corporation.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||+4°C|
Avoid freeze/thaw cycles.
Do not freeze.
Protect from light.
|Use/Stability||Stable for at least 1 year after receipt when stored at +4°C.|
|Product Specification Sheet|
CD274 (B7-H1; PD-L1; Programmed Death Ligand) is a member of the B7 family and is expressed on a variety of tissues including lymphoid cells. It plays an important role in regulation of T cell activation and is involved in progression of cancer, arthritis and HIV infection. CD274 binding to its receptor CD279 (PD-1) on activated T cells can decrease proliferation. Conversely, ligation of CD279 on primed T cells can stimulate IL-10 production. High levels of CD274 present in renal cell carcinoma is associated with poor prognosis. Tumor expressed CD274 can increase apoptosis of tumor specific T cells resulting in better tumor cell survival.